Development and validation of donor adverse reaction severity grading tool: enhancing objective grade assignment to donor adverse events

BACKGROUND Uniform and consistent reporting and comparison of donor adverse events (DAEs) and severity are well‐recognized challenges for donor hemovigilance (DHV). While the 2014 Standard for Surveillance of Complications Related to Blood Donation (SSCRBD), developed by hemovigilance experts from A...

Full description

Saved in:
Bibliographic Details
Published inTransfusion (Philadelphia, Pa.) Vol. 60; no. 6; pp. 1231 - 1242
Main Authors Townsend, Mary, Kamel, Hany, Van Buren, Nancy, Wiersum‐Osselton, Johanna, Rosa‐Bray, Marilyn, Gottschall, Jerome, Rajbhandary, Srijana
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.06.2020
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract BACKGROUND Uniform and consistent reporting and comparison of donor adverse events (DAEs) and severity are well‐recognized challenges for donor hemovigilance (DHV). While the 2014 Standard for Surveillance of Complications Related to Blood Donation (SSCRBD), developed by hemovigilance experts from AABB, the International Society of Blood Transfusion, and International Hemovigilance Network, established the DAE definitions, no specific guidelines were provided to grade severity. A group of subject matter experts developed the Severity Grading Tool for Blood Donor Adverse Events (SGT) to enhance objective assignment of severity and conducted a study to validate the tool. STUDY DESIGN AND METHODS Between January 8, 2019, and February 28, 2019, participants graded severity of 32 cases (34 DAEs) using the SGT. Comments boxes allowed participants to provide rationale for selecting a severity grade for each case. Agreement with expert grading among study participants was evaluated using percentage agreement. Inter‐rater reliability was evaluated by Kendallʼs coefficient of concordance (W). The final SGT was revised based on validation study results and feedback received. RESULTS The overall agreement was almost perfect with W = 0.84 (confidence interval [CI], 0.78‐0.90). Of 34 DAEs, respondent agreement with expert grading of more than 90% was reached for 18 DAEs, 80% to 90% for six DAEs, 70% to 80% for six DAEs, and less than 70% for four DAEs. CONCLUSION The development and validation of a uniform SGT with objective criteria for assigning severity of DAEs used together with standard reaction definitions will provide opportunities for comparison between blood centers and systems to enhance the field of DHV. See editorial on page 1115–1117, in this issue
AbstractList BACKGROUNDUniform and consistent reporting and comparison of donor adverse events (DAEs) and severity are well‐recognized challenges for donor hemovigilance (DHV). While the 2014 Standard for Surveillance of Complications Related to Blood Donation (SSCRBD), developed by hemovigilance experts from AABB, the International Society of Blood Transfusion, and International Hemovigilance Network, established the DAE definitions, no specific guidelines were provided to grade severity. A group of subject matter experts developed the Severity Grading Tool for Blood Donor Adverse Events (SGT) to enhance objective assignment of severity and conducted a study to validate the tool.STUDY DESIGN AND METHODSBetween January 8, 2019, and February 28, 2019, participants graded severity of 32 cases (34 DAEs) using the SGT. Comments boxes allowed participants to provide rationale for selecting a severity grade for each case. Agreement with expert grading among study participants was evaluated using percentage agreement. Inter‐rater reliability was evaluated by Kendallʼs coefficient of concordance (W). The final SGT was revised based on validation study results and feedback received.RESULTSThe overall agreement was almost perfect with W = 0.84 (confidence interval [CI], 0.78‐0.90). Of 34 DAEs, respondent agreement with expert grading of more than 90% was reached for 18 DAEs, 80% to 90% for six DAEs, 70% to 80% for six DAEs, and less than 70% for four DAEs.CONCLUSIONThe development and validation of a uniform SGT with objective criteria for assigning severity of DAEs used together with standard reaction definitions will provide opportunities for comparison between blood centers and systems to enhance the field of DHV.
See editorial on page 1115–1117, in this issue
Uniform and consistent reporting and comparison of donor adverse events (DAEs) and severity are well-recognized challenges for donor hemovigilance (DHV). While the 2014 Standard for Surveillance of Complications Related to Blood Donation (SSCRBD), developed by hemovigilance experts from AABB, the International Society of Blood Transfusion, and International Hemovigilance Network, established the DAE definitions, no specific guidelines were provided to grade severity. A group of subject matter experts developed the Severity Grading Tool for Blood Donor Adverse Events (SGT) to enhance objective assignment of severity and conducted a study to validate the tool. Between January 8, 2019, and February 28, 2019, participants graded severity of 32 cases (34 DAEs) using the SGT. Comments boxes allowed participants to provide rationale for selecting a severity grade for each case. Agreement with expert grading among study participants was evaluated using percentage agreement. Inter-rater reliability was evaluated by Kendall's coefficient of concordance (W). The final SGT was revised based on validation study results and feedback received. The overall agreement was almost perfect with W = 0.84 (confidence interval [CI], 0.78-0.90). Of 34 DAEs, respondent agreement with expert grading of more than 90% was reached for 18 DAEs, 80% to 90% for six DAEs, 70% to 80% for six DAEs, and less than 70% for four DAEs. The development and validation of a uniform SGT with objective criteria for assigning severity of DAEs used together with standard reaction definitions will provide opportunities for comparison between blood centers and systems to enhance the field of DHV.
BACKGROUND Uniform and consistent reporting and comparison of donor adverse events (DAEs) and severity are well‐recognized challenges for donor hemovigilance (DHV). While the 2014 Standard for Surveillance of Complications Related to Blood Donation (SSCRBD), developed by hemovigilance experts from AABB, the International Society of Blood Transfusion, and International Hemovigilance Network, established the DAE definitions, no specific guidelines were provided to grade severity. A group of subject matter experts developed the Severity Grading Tool for Blood Donor Adverse Events (SGT) to enhance objective assignment of severity and conducted a study to validate the tool. STUDY DESIGN AND METHODS Between January 8, 2019, and February 28, 2019, participants graded severity of 32 cases (34 DAEs) using the SGT. Comments boxes allowed participants to provide rationale for selecting a severity grade for each case. Agreement with expert grading among study participants was evaluated using percentage agreement. Inter‐rater reliability was evaluated by Kendallʼs coefficient of concordance (W). The final SGT was revised based on validation study results and feedback received. RESULTS The overall agreement was almost perfect with W = 0.84 (confidence interval [CI], 0.78‐0.90). Of 34 DAEs, respondent agreement with expert grading of more than 90% was reached for 18 DAEs, 80% to 90% for six DAEs, 70% to 80% for six DAEs, and less than 70% for four DAEs. CONCLUSION The development and validation of a uniform SGT with objective criteria for assigning severity of DAEs used together with standard reaction definitions will provide opportunities for comparison between blood centers and systems to enhance the field of DHV. See editorial on page 1115–1117, in this issue
Uniform and consistent reporting and comparison of donor adverse events (DAEs) and severity are well-recognized challenges for donor hemovigilance (DHV). While the 2014 Standard for Surveillance of Complications Related to Blood Donation (SSCRBD), developed by hemovigilance experts from AABB, the International Society of Blood Transfusion, and International Hemovigilance Network, established the DAE definitions, no specific guidelines were provided to grade severity. A group of subject matter experts developed the Severity Grading Tool for Blood Donor Adverse Events (SGT) to enhance objective assignment of severity and conducted a study to validate the tool.BACKGROUNDUniform and consistent reporting and comparison of donor adverse events (DAEs) and severity are well-recognized challenges for donor hemovigilance (DHV). While the 2014 Standard for Surveillance of Complications Related to Blood Donation (SSCRBD), developed by hemovigilance experts from AABB, the International Society of Blood Transfusion, and International Hemovigilance Network, established the DAE definitions, no specific guidelines were provided to grade severity. A group of subject matter experts developed the Severity Grading Tool for Blood Donor Adverse Events (SGT) to enhance objective assignment of severity and conducted a study to validate the tool.Between January 8, 2019, and February 28, 2019, participants graded severity of 32 cases (34 DAEs) using the SGT. Comments boxes allowed participants to provide rationale for selecting a severity grade for each case. Agreement with expert grading among study participants was evaluated using percentage agreement. Inter-rater reliability was evaluated by Kendall's coefficient of concordance (W). The final SGT was revised based on validation study results and feedback received.STUDY DESIGN AND METHODSBetween January 8, 2019, and February 28, 2019, participants graded severity of 32 cases (34 DAEs) using the SGT. Comments boxes allowed participants to provide rationale for selecting a severity grade for each case. Agreement with expert grading among study participants was evaluated using percentage agreement. Inter-rater reliability was evaluated by Kendall's coefficient of concordance (W). The final SGT was revised based on validation study results and feedback received.The overall agreement was almost perfect with W = 0.84 (confidence interval [CI], 0.78-0.90). Of 34 DAEs, respondent agreement with expert grading of more than 90% was reached for 18 DAEs, 80% to 90% for six DAEs, 70% to 80% for six DAEs, and less than 70% for four DAEs.RESULTSThe overall agreement was almost perfect with W = 0.84 (confidence interval [CI], 0.78-0.90). Of 34 DAEs, respondent agreement with expert grading of more than 90% was reached for 18 DAEs, 80% to 90% for six DAEs, 70% to 80% for six DAEs, and less than 70% for four DAEs.The development and validation of a uniform SGT with objective criteria for assigning severity of DAEs used together with standard reaction definitions will provide opportunities for comparison between blood centers and systems to enhance the field of DHV.CONCLUSIONThe development and validation of a uniform SGT with objective criteria for assigning severity of DAEs used together with standard reaction definitions will provide opportunities for comparison between blood centers and systems to enhance the field of DHV.
Author Townsend, Mary
Wiersum‐Osselton, Johanna
Rosa‐Bray, Marilyn
Gottschall, Jerome
Rajbhandary, Srijana
Van Buren, Nancy
Kamel, Hany
Author_xml – sequence: 1
  givenname: Mary
  orcidid: 0000-0001-7759-0676
  surname: Townsend
  fullname: Townsend, Mary
  email: mtownsend@vitalant.org
  organization: Vitalant
– sequence: 2
  givenname: Hany
  surname: Kamel
  fullname: Kamel, Hany
  organization: Vitalant
– sequence: 3
  givenname: Nancy
  surname: Van Buren
  fullname: Van Buren, Nancy
  organization: Innovative Blood Resources
– sequence: 4
  givenname: Johanna
  orcidid: 0000-0003-3451-9911
  surname: Wiersum‐Osselton
  fullname: Wiersum‐Osselton, Johanna
  organization: Sanquin Blood Bank
– sequence: 5
  givenname: Marilyn
  surname: Rosa‐Bray
  fullname: Rosa‐Bray, Marilyn
  organization: Biomat USA, Inc.–Grifols
– sequence: 6
  givenname: Jerome
  surname: Gottschall
  fullname: Gottschall, Jerome
  organization: Versiti Wisconsin
– sequence: 7
  givenname: Srijana
  surname: Rajbhandary
  fullname: Rajbhandary, Srijana
  organization: AABB
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32452048$$D View this record in MEDLINE/PubMed
BookMark eNp1kc1OGzEURq2KqgTogheoLLEpiwH_znjYISgUCakSomvL8dwJjiZ2ajup8gY8ds0kbKLijWX5fMfW_Y7QgQ8eEDql5IKWdZljf0Gl4uQTmlDJm4q1rTxAE0IErSjl7BAdpTQnhLCW0C_okDMhGRFqgl5vYQ1DWC7AZ2x8h9dmcJ3JLngcetwFHyI23RpiAhzB2PEmlVB0eYNn0XTOz3AOYbjC4F-Mt2_nMJ1DQdcwEoBNSm7mx0dy2LMWl8_pBH3uzZDg624_Rr_vfjzf_Kwef90_3Fw_VpZLTiojVU96wplRXBBQtK8lZ60VgshaKSVoA01tjSS1rdsptZQqwQyXDWP91AI_Rt-33mUMf1aQsl64ZGEYjIewSpoJUreiOHlBz_bQeVhFX35XKMo5bdqaFerbjlpNF9DpZXQLEzf6fcYFuNwCNoaUIvTaujxOOEfjBk2JfmtRlxb12GJJnO8l3qX_Y3f2v26Azcegfn662yb-AeDzrEY
CitedBy_id crossref_primary_10_1016_j_tracli_2022_09_070
crossref_primary_10_1111_vox_13502
crossref_primary_10_1111_vox_13048
crossref_primary_10_1111_vox_13421
crossref_primary_10_1016_j_tmrv_2023_150777
crossref_primary_10_1186_s13063_024_08035_7
crossref_primary_10_1002_jca_22146
crossref_primary_10_1111_vox_13392
crossref_primary_10_1111_trf_15854
crossref_primary_10_1177_26348535231207051
crossref_primary_10_1111_trf_16668
crossref_primary_10_1016_j_tracli_2025_03_001
crossref_primary_10_1016_j_tmrv_2024_150851
crossref_primary_10_1111_trf_16333
crossref_primary_10_1111_trf_17862
crossref_primary_10_1111_trf_16572
Cites_doi 10.1001/jama.299.19.2279
10.1111/j.1423-0410.2010.01442.x
10.1111/j.1537-2995.2011.03401.x
10.1111/trf.15133
10.1111/vox.12323
10.4135/9781412961288
10.1016/j.biologicals.2011.12.003
10.1111/j.1537-2995.2007.01163.x
10.1111/j.1423-0410.1998.tb05454.x
10.1136/bmj.331.7520.800-c
10.1111/trf.14948
10.1182/blood-2018-09-873125
10.1111/trf.14921
10.1111/j.1537-2995.2011.03074.x
ContentType Journal Article
Copyright 2020 AABB
2020 AABB.
Copyright_xml – notice: 2020 AABB
– notice: 2020 AABB.
DBID AAYXX
CITATION
NPM
7QO
7U9
8FD
FR3
H94
K9.
P64
7X8
DOI 10.1111/trf.15830
DatabaseName CrossRef
PubMed
Biotechnology Research Abstracts
Virology and AIDS Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
Virology and AIDS Abstracts
Biotechnology Research Abstracts
Technology Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList Virology and AIDS Abstracts
CrossRef
PubMed

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1537-2995
EndPage 1242
ExternalDocumentID 32452048
10_1111_trf_15830
TRF15830
Genre article
Journal Article
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
123
1OB
1OC
29Q
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5HH
5LA
5RE
5VS
66C
6PF
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANLZ
AAONW
AAQQT
AASGY
AAWTL
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABLJU
ABPVW
ABQWH
ABXGK
ACAHQ
ACBNA
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHMBA
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EGARE
EJD
EMOBN
ESX
EX3
F00
F5P
FUBAC
G-S
G.N
GODZA
H.X
HF~
HGLYW
HZI
HZ~
H~9
IHE
IX1
J0M
J5H
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SJN
SUPJJ
TEORI
TWZ
UB1
UCJ
V8K
V9Y
W8V
W99
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WUP
WVDHM
WXI
WXSBR
X7M
XG1
YFH
YQI
YQJ
YUY
ZGI
ZXP
ZZTAW
~IA
~WT
AAYXX
ABJNI
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
NPM
YIN
7QO
7U9
8FD
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
FR3
H94
K9.
P64
7X8
ID FETCH-LOGICAL-c3530-a58f0f032a8340e81f65329c44056888417e76ca506c69b1c11842a35722fbce3
IEDL.DBID DR2
ISSN 0041-1132
1537-2995
IngestDate Fri Jul 11 10:52:51 EDT 2025
Wed Aug 13 06:58:38 EDT 2025
Wed Feb 19 02:29:49 EST 2025
Thu Apr 24 22:55:54 EDT 2025
Tue Jul 01 00:28:32 EDT 2025
Wed Jan 22 16:33:09 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
License 2020 AABB.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3530-a58f0f032a8340e81f65329c44056888417e76ca506c69b1c11842a35722fbce3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ORCID 0000-0001-7759-0676
0000-0003-3451-9911
PMID 32452048
PQID 2413317962
PQPubID 1096380
PageCount 12
ParticipantIDs proquest_miscellaneous_2406945323
proquest_journals_2413317962
pubmed_primary_32452048
crossref_citationtrail_10_1111_trf_15830
crossref_primary_10_1111_trf_15830
wiley_primary_10_1111_trf_15830_TRF15830
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate June 2020
PublicationDateYYYYMMDD 2020-06-01
PublicationDate_xml – month: 06
  year: 2020
  text: June 2020
PublicationDecade 2020
PublicationPlace Hoboken, USA
PublicationPlace_xml – name: Hoboken, USA
– name: United States
– name: Bethesda
PublicationTitle Transfusion (Philadelphia, Pa.)
PublicationTitleAlternate Transfusion
PublicationYear 2020
Publisher John Wiley & Sons, Inc
Wiley Subscription Services, Inc
Publisher_xml – name: John Wiley & Sons, Inc
– name: Wiley Subscription Services, Inc
References 2005; 331
2010
2011; 51
2019; 59
2019
2016; 110
1998; 74
2008; 299
2019; 133
2011; 100
2007; 47
2012; 52
2018; 58
2012; 40
e_1_2_7_6_1
e_1_2_7_5_1
American Association of Blood Bank (AABB) (e_1_2_7_20_1) 2019
e_1_2_7_4_1
e_1_2_7_3_1
e_1_2_7_9_1
e_1_2_7_8_1
e_1_2_7_7_1
e_1_2_7_19_1
e_1_2_7_18_1
e_1_2_7_17_1
e_1_2_7_16_1
e_1_2_7_2_1
e_1_2_7_15_1
e_1_2_7_14_1
e_1_2_7_13_1
e_1_2_7_12_1
e_1_2_7_11_1
e_1_2_7_10_1
e_1_2_7_21_1
References_xml – volume: 59
  start-page: 1706
  year: 2019
  end-page: 16
  article-title: Elevated risk for iron depletion in high‐school age blood donors
  publication-title: Transfusion
– volume: 52
  start-page: 702
  year: 2012
  end-page: 11
  article-title: Iron deficiency in blood donors: the REDS‐II Donor Iron Status Evaluation (RISE) study
  publication-title: Transfusion
– volume: 110
  start-page: 185
  year: 2016
  end-page: 8
  article-title: Development of standard definitions for surveillance of complications related to blood donation
  publication-title: Vox Sang
– volume: 58
  start-page: 2589
  year: 2018
  end-page: 95
  article-title: International validation of harmonized definitions for complications of blood donations
  publication-title: Transfusion
– volume: 299
  start-page: 2297
  year: 2008
  end-page: 86
  article-title: Adverse reactions to allogeneic whole blood donation by 16‐ and 17‐year‐olds
  publication-title: JAMA
– volume: 100
  start-page: 60
  year: 2011
  end-page: 7
  article-title: Hemovigilance: an effective tool for improving transfusion practice
  publication-title: Vox Sang
– volume: 51
  start-page: 1511
  year: 2011
  end-page: 21
  article-title: Interventions to reduce the vasovagal rate in young whole blood donors
  publication-title: Transfusion
– volume: 47
  start-page: 621
  year: 2007
  end-page: 8
  article-title: A revised classification scheme for acute transfusion reactions
  publication-title: Transfusion
– start-page: 19
  year: 2019
– volume: 133
  start-page: 605
  year: 2019
  end-page: 14
  article-title: Plateletpheresis‐associated lymphopenia in frequent platelet donors
  publication-title: Blood
– volume: 74
  start-page: 441
  issue: Suppl 2
  year: 1998
  end-page: 5
  article-title: The French haemovigilance system
  publication-title: Vox Sang
– volume: 331
  start-page: 800
  year: 2005
  article-title: EU tightens rules on blood safety
  publication-title: BMJ
– volume: 40
  start-page: 176
  year: 2012
  end-page: 9
  article-title: Donor vigilance: what are we doing about it?
  publication-title: Biologicals
– volume: 58
  start-page: 2861
  year: 2018
  end-page: 7
  article-title: Ferritin testing to characterize and address iron deficiency in young donors
  publication-title: Transfusion
– year: 2010
– ident: e_1_2_7_5_1
  doi: 10.1001/jama.299.19.2279
– ident: e_1_2_7_16_1
– ident: e_1_2_7_4_1
  doi: 10.1111/j.1423-0410.2010.01442.x
– ident: e_1_2_7_8_1
  doi: 10.1111/j.1537-2995.2011.03401.x
– ident: e_1_2_7_9_1
  doi: 10.1111/trf.15133
– ident: e_1_2_7_11_1
  doi: 10.1111/vox.12323
– ident: e_1_2_7_19_1
– ident: e_1_2_7_18_1
  doi: 10.4135/9781412961288
– ident: e_1_2_7_6_1
  doi: 10.1016/j.biologicals.2011.12.003
– ident: e_1_2_7_14_1
  doi: 10.1111/j.1537-2995.2007.01163.x
– ident: e_1_2_7_2_1
  doi: 10.1111/j.1423-0410.1998.tb05454.x
– ident: e_1_2_7_3_1
  doi: 10.1136/bmj.331.7520.800-c
– ident: e_1_2_7_17_1
– ident: e_1_2_7_13_1
  doi: 10.1111/trf.14948
– ident: e_1_2_7_21_1
  doi: 10.1182/blood-2018-09-873125
– ident: e_1_2_7_10_1
  doi: 10.1111/trf.14921
– ident: e_1_2_7_7_1
  doi: 10.1111/j.1537-2995.2011.03074.x
– ident: e_1_2_7_12_1
– start-page: 19
  volume-title: Standard 5.4.3.
  year: 2019
  ident: e_1_2_7_20_1
– ident: e_1_2_7_15_1
SSID ssj0002901
Score 2.4103339
Snippet BACKGROUND Uniform and consistent reporting and comparison of donor adverse events (DAEs) and severity are well‐recognized challenges for donor hemovigilance...
See editorial on page 1115–1117, in this issue
Uniform and consistent reporting and comparison of donor adverse events (DAEs) and severity are well-recognized challenges for donor hemovigilance (DHV). While...
BACKGROUNDUniform and consistent reporting and comparison of donor adverse events (DAEs) and severity are well‐recognized challenges for donor hemovigilance...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1231
SubjectTerms Agreements
Blood & organ donations
Blood donors
Blood transfusion
Complications
Confidence intervals
Evaluation
Reliability analysis
Transfusion
Title Development and validation of donor adverse reaction severity grading tool: enhancing objective grade assignment to donor adverse events
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Ftrf.15830
https://www.ncbi.nlm.nih.gov/pubmed/32452048
https://www.proquest.com/docview/2413317962
https://www.proquest.com/docview/2406945323
Volume 60
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB6tOKBeWqAPFihyUQ-9ZBXbeS2cUMUKIcEBgcQBKbIdB2hRgnazF34BP5sZO0mXl4R6S5TJy56xv_GMvwH4abg1qjDjoCT-y4iScnQZFkFKNKgFl4X0CbInyeF5dHQRXwxgr9sL4_kh-gU3sgw3XpOBKz1bMPJmWo54nEny1ylXiwDR6T_qKIoP-ugyD6iaessqRFk8_Z1P56IXAPMpXnUTzuQTXHaf6vNM_o7mjR6Z-2csjv_5LyvwsQWibN9rzioMbLUGy8dtqP0zPCykEzFVFQxV8sYXYGJ1yYq6qqdMUTnnmWWIPN3-CIbzrKVyeOxq6pLzWVPXt7vMVtfE64Hntf7jh1gnYRli95srl5GAos-e6silZl_gfHJw9vswaMs2BEbGMgxUnJVhGUqhMhmFNuMl9rsYmwixYYIOd8RTmyZUiiExyVhzgz5OJJSMUyFKbaz8CktVXdl1YCINU2F5gl6jiHRqlCC-e51kCEtjnmZD-NV1YG5aTnMqrXGbd74NtmzuWnYIO73onSfyeE1oq9OCvLXlWU6RR0RZ40QM4Ud_Ga2QQiuqsvWcZGgDMf6mHMI3rz39WyQFt3GgxI91OvD26_Oz04k72Hi_6CZ8ELQE4BaGtmCpmc7td8RJjd52BvEI30MNvw
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDCaCFuh62XtttmzVhh52cWBJfmXYZRgWpF2TQ5ACvRSGLctZ1sAeEufSX7CfPVKy3eeAojcbpl8SKX0UqY8Ah4prlWRq4OTEf-lRUk6au5kTEg1qxmUmbYLsJBidesdn_lkHvjZ7YSw_RLvgRpZhxmsycFqQvmbl1Srvcz-S6LBvU0Vv41BNr8ijKEJo48vcoXrqNa8Q5fG0t96cje5AzJuI1Uw5w2dw3nyszTS56G-qtK8ub_E4PvZvnsPTGouyb1Z5XkBHFy9hZ1xH21_B32sZRSwpMoZaubA1mFiZs6wsyhVLqKLzWjMEn2aLBMOpVlNFPDZfmfx8VpXl8gvTxS-i9sDzMv1tR1kjoRnC98XcJCWg6K2nGn6p9Ws4Hf6YfR85deUGR0lfuk7iR7mbu1IkkfRcHfEcu14MlIfwMECf2-OhDgOqxhCoYJByhW6OJxLph0LkqdLyDWwVZaH3gYnQDYXmATqOwktDlQiivE-DCJGpz8OoC5-bHoxVTWtO1TWWcePeYMvGpmW78KkV_WO5PO4T6jVqENfmvI4p-IhAaxCILnxsL6MhUnQlKXS5IRnaQ4y_KbuwZ9WnfYuk-DaOlfixRgn-__p4Nh2ag7cPFz2AJ6PZ-CQ-OZr8fAe7glYEzDpRD7aq1Ua_R9hUpR-MdfwDrAsR2g
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4hKqFeoE_Ydtu6qIdesortxMm2p6p0BS0ghEDigBQljr2loGS1m730F_Rnd8ZOUqCthLglyuRlz9jfeMbfALzT3Oi81OPAEv9lREk5hQ3LICEa1JLLUvoE2UO1exp9PYvPVuBjtxfG80P0C25kGW68JgOflfaakTdzO-JxKtFffxCpMCWV3jn-wx1FAUIfXuYBlVNvaYUojae_9eZk9BfCvAlY3Ywz2YDz7lt9osnlaNkUI_3zFo3jPX_mEay3SJR98qrzGFZM9QTWDtpY-1P4dS2fiOVVyVAnL3wFJlZbVtZVPWc51XNeGIbQ022QYDjRGqqHx6Zzl53Pmrq--sBM9Z2IPfC8Ln74MdZJGIbg_WLqUhJQ9NZTHbvU4hmcTr6cfN4N2roNgZaxDIM8Tm1oQynyVEahSbnFjhdjHSE4VOhxRzwxiaJaDEqrccE1OjmRyGWcCGELbeRzWK3qymwBE0mYCMMVuo0iKhKdCyK8L1SKuDTmSTqA910HZrolNafaGldZ59xgy2auZQew3YvOPJPHv4SGnRZkrTEvMgo9IswaKzGAt_1lNEOKreSVqZckQzuI8TflADa99vRvkRTdxpESP9bpwP9fn50cT9zBi7uLvoG1o51Jtr93-O0lPBS0HOAWiYaw2syX5hVipqZ47WzjN4eXEJI
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+and+validation+of+donor+adverse+reaction+severity+grading+tool%3A+enhancing+objective+grade+assignment+to+donor+adverse+events&rft.jtitle=Transfusion+%28Philadelphia%2C+Pa.%29&rft.au=Townsend%2C+Mary&rft.au=Kamel%2C+Hany&rft.au=Van+Buren%2C+Nancy&rft.au=Wiersum%E2%80%90Osselton%2C+Johanna&rft.date=2020-06-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.issn=0041-1132&rft.eissn=1537-2995&rft.volume=60&rft.issue=6&rft.spage=1231&rft.epage=1242&rft_id=info:doi/10.1111%2Ftrf.15830&rft.externalDBID=10.1111%252Ftrf.15830&rft.externalDocID=TRF15830
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0041-1132&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0041-1132&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0041-1132&client=summon